Two Institutions Publish Independent Data on Novocure’s Tumor Treating Fields
September 14 2016 - 8:00AM
Business Wire
Publications represent growing interest from
scientific community in Novocure’s broadly applicable mechanism of
action
Novocure (NASDAQ: NVCR) announced today that two independent
institutions published scientific research on Tumor Treating Fields
(TTFields), representing increasing external interest from the
scientific community in Novocure’s innovative, proprietary therapy.
The published data support Novocure’s existing body of research
establishing TTFields as a low-toxicity, effective cancer treatment
while adding new insights to the mechanism of action beyond the
known anti-mitotic properties of this modality. The following
articles were published:
- Kim et al. “Biological effect of an
alternating electric field on cell proliferation and synergistic
antimitotic effect in combination with ionizing radiation.”
Oncotarget, Aug. 19, 2016; Korea Institute of Radiological &
Medical Sciences and Department of Bio-Convergence Engineering,
Korea University
- Kim et al. “Tumor treating fields
inhibit glioblastoma cell migration, invasion and angiogenesis.”
Oncotarget, Aug. 18, 2016; Korea Institute of Radiological &
Medical Sciences and Department of Bio-Convergence Engineering,
Korea University
- Pavesi et al. “Engineering a 3D
microfluidic culture platform for tumor-treating field
application.” Scientific Reports, May 24, 2016; Singapore–MIT
Alliance for Research and Technology, BioSystems
“We have been interested in learning more about Novocure’s
treatment with TTFields for some time and were eager to conduct our
own research,” said Myonggeun Yoon, a Professor at the School
of Biomedical Engineering, Korea University. “TTFields is a
promising, novel cancer treatment with broad applicability, and we
look forward to seeing how the research on TTFields will
evolve.”
“Based on the growing interest in TTFields, we decided to
develop a microfluidic system that can be used to rapidly screen
the effect of this emerging modality on both cancer and normal
cells within an in vivo like microenvironment,” said Dr. Andrea
Pavesi, a research scientist from the Singapore–MIT Alliance for
Research and Technology (SMART). “Indeed, using our novel device,
we were able to demonstrate that TTFields application selectively
targeted cancer cells while minimally affecting endothelial cells,”
added Dr. Giulia Adriani, also research scientist at SMART.
Internationally, over 20 institutions are studying TTFields,
including 10 that are using Novocure’s inovitro system, a lab
research tool that allows investigators to efficiently study the
effects of different field parameters and TTFields’ synergies with
various drug and radiation combinations.
“We are excited that an increasing number of independent
institutions are studying TTFields and supplementing the research
we have conducted thus far,” said Dr. Eilon Kirson, Chief Science
Officer and Head of Research and Development at Novocure. “We
believe greater interest in TTFields from the scientific community
will help us raise awareness of our innovative cancer therapy.”
About Novocure
Novocure is a commercial-stage oncology company developing a
proprietary therapy called Tumor Treating Fields, or TTFields, for
the treatment of solid tumor cancers. Headquartered in Jersey,
Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania, and New York City.
Additionally, the company has offices
in Germany, Switzerland and Japan, and a
research center in Haifa, Israel. For additional information
about the company, please visit www.novocure.com or
follow us at www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, development of potential products,
interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market
prospects for its products, and other statements regarding matters
that are not historical facts. You may identify some of these
forward-looking statements by the use of words in the statements
such as "anticipate," "estimate," "expect," "project," "intend,"
"plan," "believe" or other words and terms of similar meaning.
Novocure's performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, regulatory and political
conditions as well as more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on March 1, 2016, with the U.S. Securities and Exchange
Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend
to update publicly any forward-looking statement, except as
required by law. Any forward-looking statements herein speak only
as of the date hereof. The Private Securities Litigation Reform Act
of 1995 permits this discussion.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160914005621/en/
Media and Investor Contact:NovocureAshley Cordova,
212-767-7558acordova@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2023 to Apr 2024